Instructions for Xefocam Rapid (Lornoxicam) 8 mg 12 pills
English product name
Xefocam rapid
Release form
Coated tablets
Description:
The tablets, which are coated with a film shell in a white to light yellow colour, are round and double-convex.
1 tab.
lornoxicam 8 mg
Auxiliary substances:
calcium stearate - 1.6 mg,
hyprolose - 16 mg,
sodium hydrogen carbonate - 40 mg,
hyprolose low - 48 mg,
microcrystalline cellulose - 96 mg,
calcium hydrophosphate anhydrous - 110.4 mg.
Film sheath composition:
propylene glycol - about 1.1 mg,
talc - about 3.6 mg,
titanium dioxide - about 3.6 mg,
hypromellose - about 5.7 mg.
ATC codes
M01AC05 Lornoxicam
Clinical-pharmacological groups / Group affiliation
NAPS
Active substance
lornoxicam
Pharmacotherapy group:
NSAIDs
Storage Conditions
The drug should be stored in a place inaccessible to children at a temperature not higher than 30 ° C.
Best before date
Shelf life is 2 years. Do not apply after expiry date.
Testimony:
short-term treatment of mild to moderate intensity pain syndrome.
Method of use, course and dosage:
The drug is taken inside, having enough liquid.
The dose of lornoxicam is 8-16 mg, a single dose is 8 mg. In the first day of treatment, the drug is prescribed in an initial dose of 16 mg, twelve hours after its use - in a dose of eight mg. The maximum recommended daily dose is 16 mg.
A special dose selection for elderly patients (over 65 years of age) is not required if there is no impairment of kidney or liver function. The drug should be prescribed with caution, because in this age group, unwanted effects from the gastrointestinal tract are worse.
Patients with kidney failure may require a dose correction.
Patients with liver dysfunction may require a dose correction.
Undesirable effects can be minimized by using the lowest effective dose of the drug for the shortest amount of time necessary to control symptoms.
Application for kidney disorders
It is contraindicated in severe renal insufficiency (serum creatinine level over 700 mmol/l), progressive kidney diseases.
With caution: In case of kidney dysfunction mild (150-300 mkmol/l serum creatinine) and moderate degree (300-700 mkmol/l serum creatinine).
Use in liver disorders
It is contraindicated in severe liver failure.
With caution: Liver function (cirrhosis).
Terms of Sale
The drug is prescription.
Application in elderly patients
Patients over 65 years of age are given the drug with caution (control of liver and kidney function is recommended).
Use in children
The use of the preparation in the age of up to 18 years is contraindicated.
- Nosology (ICD codes)
- R52.0
- Acute pain
- R52.2
- Other persistent pain (chronic)
Pharmacological effect:
NSAIDs are classified as oxycams. It has a pronounced analgesic and anti-inflammatory effect.
The mechanism of action is based on the suppression of prostaglandin synthesis (inhibition of the enzyme COX), leading to a reduction in inflammation.
Lornoxicam does not affect the basic indicators of the body: Body temperature, HSS, AD, ECG data, spirometry.
The analgesic effect of lornoxicam is not related to narcotic action. The drug Xefocam rapide does not have an opiate-like effect on the CNS and, unlike narcotic analgesics, does not inhibit breathing, does not cause drug dependence.
Due to the presence of a local irritant effect on the gastrointestinal tract and a systemic ulcerogenic effect associated with the suppression of prostaglandin synthesis, complications from the gastrointestinal tract are frequent undesirable effects in the treatment of NSAIDs.
